Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

997 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.
Dimopoulos MA, Petrucci MT, Foà R, Catalano J, Kropff M, Terpos E, Zhang J, Grote L, Jacques C, Palumbo A; MM-015 Investigators. Dimopoulos MA, et al. Among authors: palumbo a. Haematologica. 2015 Aug;100(8):e328-30. doi: 10.3324/haematol.2014.120790. Epub 2015 Apr 3. Haematologica. 2015. PMID: 25840600 Free PMC article. Clinical Trial. No abstract available.
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Dimopoulos MA, Delforge M, Hájek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A. Dimopoulos MA, et al. Among authors: palumbo a. Haematologica. 2013 May;98(5):784-8. doi: 10.3324/haematol.2012.074534. Epub 2012 Dec 14. Haematologica. 2013. PMID: 23242595 Free PMC article. Clinical Trial.
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Dimopoulos MA, Palumbo A, Hajek R, Kropff M, Petrucci MT, Lewis P, Millar S, Zhang J, Mei J, Delforge M. Dimopoulos MA, et al. Among authors: palumbo a. Leuk Lymphoma. 2014 Jul;55(7):1489-97. doi: 10.3109/10428194.2013.847933. Epub 2013 Dec 17. Leuk Lymphoma. 2014. PMID: 24144308 Free PMC article. Clinical Trial.
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. Palumbo A, et al. J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282661 Free article. Clinical Trial.
Clinical characteristics of patients with relapsed multiple myeloma.
Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Dimopoulos MA, et al. Among authors: palumbo a. Cancer Treat Rev. 2015 Dec;41(10):827-35. doi: 10.1016/j.ctrv.2015.07.005. Epub 2015 Jul 31. Cancer Treat Rev. 2015. PMID: 26296679 Free article. Review.
Treatment of relapsed/refractory multiple myeloma.
Kastritis E, Palumbo A, Dimopoulos MA. Kastritis E, et al. Among authors: palumbo a. Semin Hematol. 2009 Apr;46(2):143-57. doi: 10.1053/j.seminhematol.2009.01.004. Semin Hematol. 2009. PMID: 19389498 Review.
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF. Dimopoulos MA, et al. Among authors: palumbo a. Eur J Haematol. 2011 Jan;86(1):23-31. doi: 10.1111/j.1600-0609.2010.01533.x. Epub 2010 Nov 15. Eur J Haematol. 2011. PMID: 20874823 Clinical Trial.
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Palumbo A, et al. N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. N Engl J Med. 2012. PMID: 22571200 Free article. Clinical Trial.
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.
Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. Engelhardt M, et al. Among authors: palumbo a. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358. Haematologica. 2014. PMID: 24497560 Free PMC article.
997 results